Rare Medical News

Spotlight On

IgA nephropathy

IgA nephropathy is a disease in which IgA protein builds up in and damages the filtering part of the kidney (glomerulus)



US Estimated


Europe Estimated

Age of Onset





Autosomal dominant


Autosomal recessive




X-linked dominant


X-linked recessive


Rare View

IgA nephropathy is a chronic glomerulonephritis characterized by the deposition of IgA immune complexes in glomeruli. The classic presentation for the non-aggressive form (in 40–50% of the cases) is episodic hematuria, which usually starts within a day or two of a non-specific upper respiratory tract infection. n 1968, Jean Berger (1930–2011), a pioneering French nephrologist, was the first to describe IgA deposition in this form of glomerulonephritis and therefore it is sometimes called Berger’s disease.

5 Facts you should know



Primary IgA nephropathy is characterized by deposition of the IgA antibody in the glomerulus



IgA nephropathy can occur at any age, even in childhood



It affects men 2-6 times more frequently than women



Asians and whites are more likely to be affected



In non-aggressive IgA nephropathy there is traditionally a slow progression to chronic kidney failure in 20–40% of cases

IgA nephropathy is also known as...

IgA nephropathy

Berger's disease, synpharyngitic glomerulonephritis, IGAN; Glomerulonephritis, IGA

What’s your Rare IQ?

What is the most common presenting symptom of IgA nephropathy?

Common signs & symptoms


Joint pain

Autosomal dominant inheritance


Blood in urine


IgA deposition in the glomerulus


Kidney inflammation


High urine protein levels


Red or purple spots on the skin

Top Clinical Trials

TitleDescriptionPhasesStatusInterventionsMore Information
Open-Label Extension Study of BION-1301 in IgA NephropathyThis is an open-label extension (OLE) study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of BION-1301 in adults with IgA nephropathyPhase 2RecruitingDrug: BION-1301Click here for more information
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsThe study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of LNP023 at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.Phase 3RecruitingDrug: Placebo|Drug: LNP023Click here for more information
A Study of Telitacicept for Injection (RC18) in Subjects With IgA NephropathyThis is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.Phase 2RecruitingDrug: Telitacicept 160mg|Drug: Telitacicept 240mg|Drug: PlaceboClick here for more information
Atacicept in Subjects With IgA NephropathyThe objective of the study is to evaluate the effect of atacicept compared to placebo on change in proteinuria in adult subjects with IGAN.Phase 2RecruitingBiological: Atacicept|Other: Placebo to match AtaciceptClick here for more information
Atrasentan in Patients With IgA NephropathyThe ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.Phase 3RecruitingDrug: Atrasentan|Drug: PlaceboClick here for more information
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) NephropathyThe overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).
Phase 3Active, not recruitingDrug: Nefecon|Drug: Placebo oral capsuleClick here for more information
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyThe purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment.
Phase 3RecruitingBiological: OMS721|Other: Vehicle (D5W or saline)Click here for more information
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyTo determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Phase 3Active, not recruitingDrug: sparsentan|Drug: irbesartanClick here for more information
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).Phase 1|Phase 2RecruitingDrug: BION-1301 Single Dose|Drug: Placebo Single Dose|Drug: BION-1301 Multiple Doses|Drug: Placebo Multiple DosesClick here for more information
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA NephropathyRandomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgANPhase 2RecruitingDrug: Felzartamab|Other: PlaceboClick here for more information

Top Treatments in Research

AgentClass/Mechanism of ActionDevelopment StatusCompanyClinical StudiesMore Information
BION-1301An investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors,Phase 2Chinook Therapeutics, Inc.Click here for more informationClick here for more information
LNP023 (iptacopan)Iptacopan (LNP023) is an oral, first-in-class, potent and selective small-molecule inhibitor of factor B (FB)Phase 3NovartisClick here for more informationClick here for more information
TelitaciceptTelitacicept (RC18) is a first-in-class TACI-Fc fusion protein for injection which targets two important cell-signaling molecules, B-cell lymphocyte stimulator (BLyS) and A proliferation inducing ligand (APRIL).Phase 2RemegenClick here for more informationClick here for more information
AtaciceptAtacicept (TACI-Ig) is a recombinant fusion protein of the extracellular domain of TACI and the human IgG1.Fc domainPhase 2Vera Therapeutics, Inc.Click here for more informationClick here for more information
AtrasentanAtrasentan is a potent and selective, small molecule inhibitor of the endothelin A receptorPhase 3Chinook Therapeutics, Inc.Click here for more informationClick here for more information
OMS721Narsoplimab (OMS721) Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. Phase 3OmerosClick here for more informationClick here for more information
sparsentanSparsentan is a first-in-class, orally active, single molecule that functions as a high affinity dual-acting antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptorsPhase 3TravereClick here for more informationClick here for more information
FelzartamabFelzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys' HuCAL antibody library and directed against CD38.Phase 2MorphosysClick here for more informationClick here for more information
VIS649VIS649 is a humanized immunoglobulin G (IgG2) monoclonal antibody that binds to and blocks the biological actions of the cytokine A PRoliferation Inducing Ligand (APRIL)Phase 2VisterraClick here for more informationClick here for more information
RavulizumabRavulizuma, is a humanized monoclonal antibody complement inhibitor medication designed to bind to and prevent the activation of Complement component 5Phase 2AlexionClick here for more informationClick here for more information
APL-2APL-2 is an (pegcetacoplan), investigational C3-targeted inhibitorPhase 2ApellisClick here for more informationClick here for more information